Creating targeted antibodies to treat Guillain-Barré Syndrome
Development of ganglioside specific IgGs for the treatment of Guillian-Barré Syndrome
['FUNDING_R21'] · UNIVERSITY OF GEORGIA · NIH-11039976
This study is looking for new ways to help people with Guillain-Barré Syndrome by finding special antibodies that can block the harmful effects of the body’s own immune response, especially for those who haven't improved with current treatments.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF GEORGIA (nih funded) |
| Locations | 1 site (ATHENS, UNITED STATES) |
| Trial ID | NIH-11039976 on ClinicalTrials.gov |
What this research studies
This research focuses on developing specific antibodies that can target and neutralize the harmful effects of auto-antibodies associated with Guillain-Barré Syndrome (GBS), a condition often triggered by infections like Campylobacter jejuni. By screening B cells from former GBS patients, the researchers aim to identify and isolate these antibodies, which will then be tested for their effectiveness in laboratory settings. The goal is to create a new therapeutic option that could improve treatment outcomes for patients who do not respond to current therapies like intravenous immunoglobulin G (IVIg).
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who have been diagnosed with Guillain-Barré Syndrome and have not responded adequately to standard treatments.
Not a fit: Patients with Guillain-Barré Syndrome who have already responded well to existing treatments may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment option for patients with Guillain-Barré Syndrome, particularly those who do not respond to existing therapies.
How similar studies have performed: While the approach of developing specific antibodies for GBS is innovative, similar strategies in other autoimmune conditions have shown promise, indicating potential for success.
Where this research is happening
ATHENS, UNITED STATES
- UNIVERSITY OF GEORGIA — ATHENS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SZYMANSKI, CHRISTINE M. — UNIVERSITY OF GEORGIA
- Study coordinator: SZYMANSKI, CHRISTINE M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.